… In conclusion, our results suggest that valganciclovir treatment of infected fetuses is not
associated with maternal, fetal or neonatal side effects and demonstrated at least partial viral …

… for congenital CMV infections. Currently, two different antivirals are in use: oral valganciclovir
(VGC) and … The aim of our study was to analyze the available data on the VGC treatment of …

… In the case of symptomatic cCMV, we actually recommend treatment with oral valganciclovir
… Valganciclovir is reserved for congenitally-infected neonates with the symptomatic disease …

… cytomegalovirus infection at our hospital during the study period, 36 patients (47%) received
antiviral treatment. Of … Since one patient who had completed treatment with VGCV before …

… on cytomegalovirus infection in pregnancy evaluating the effect of the introduction of
valacyclovir in the clinical practice for the prevention of vertical transmission of cytomegalovirus. …

… of valganciclovir treatment for cytomegalovirus (CMV) infection … with fewer treatment-limiting
toxicities than valganciclovir. … , patients with first asymptomatic CMV infection post-HCT were …

… The aim of the present study was to investigate whether valganciclovir treatment can
prevent deterioration of hearing in children with hearing loss and clinically inapparent cCMV. …

We evaluated the therapeutic outcome of intravitreal injection (IVI) of ganciclovir with/without
oral valganciclovir for cytomegalovirus (CMV) anterior segment infection. We enrolled 61 …

… long-term valganciclovir therapy. In the first case, valganciclovir therapy was prolonged beyond
… reduction following valganciclovir administration and no adverse events, CMV viral load …

… In conclusion, the valacyclovir treatment significantly increased the portion of asymptomatic
neonates from 43%, without treatment, to 82% with treatment. There was no overlap in 95% …